These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22230300)

  • 21. Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome.
    Nair GB; Charles M; Ogden L; Spiegler P
    Respir Care; 2012 Apr; 57(4):631-3. PubMed ID: 22005027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.
    Stamatoullas A; Rezine I; Mareschal S; Ménard AL; Lanic H; David M; Daliphard S; Penther D; Lemasle E; Cassuto O; Lenain P; Contentin N; Lepretre S; Jardin F; Bastard C; Tilly H
    Leuk Lymphoma; 2016; 57(6):1491-3. PubMed ID: 26430832
    [No Abstract]   [Full Text] [Related]  

  • 23. Histiocytoid Sweet's syndrome potentially related to decitabine in a patient with myelodysplastic syndrome.
    Park JY; Park JS; Kim YC
    Eur J Dermatol; 2012; 22(6):811-2. PubMed ID: 23178879
    [No Abstract]   [Full Text] [Related]  

  • 24. Adverse effects of azacitidine: onset, duration, and treatment.
    Martínez-Francés A
    Adv Ther; 2011 Jun; 28 Suppl 4():1-5. PubMed ID: 21688206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report.
    Ponard A; Ferreira-Maldent N; Ertault M; Delain M; Amraoui K; Regina S; Jonville-Béra AP; Hérault O; Colombat P; Gyan E
    J Med Case Rep; 2018 Jul; 12(1):199. PubMed ID: 29966534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
    Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
    Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.
    Adams CD; Szumita PM; Baroletti SA; Lilly CM
    Pharmacotherapy; 2005 May; 25(5):765-8. PubMed ID: 15899739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophilic eccrine hidradenitis associated with decitabine.
    Ng ES; Aw DC; Tan KB; Poon ML; Yap ES; Liu TC; Tan LK; Chng WJ; Koh LP
    Leuk Res; 2010 May; 34(5):e130-2. PubMed ID: 20022375
    [No Abstract]   [Full Text] [Related]  

  • 30. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
    Santini V
    Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
    Komrokji R; Al Ali N; Padron E; Lancet J; Nazha A; Steensma D; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Sallman D
    Leuk Lymphoma; 2021 Nov; 62(11):2762-2767. PubMed ID: 34114922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-grade B-cell lymphoma of the peritoneum as a result of transformation of a CD5-negative monoclonal B lymphocytosis population in a patient with myelodysplastic syndrome treated with 5-azacytidine.
    Dimou M; Roumelioti M; Dimitrakopoulou A; Bitsani C; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
    Leuk Lymphoma; 2018 May; 59(5):1264-1267. PubMed ID: 28901815
    [No Abstract]   [Full Text] [Related]  

  • 33. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
    Fenaux P; Ades L
    Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents.
    Kubasch AS; Schulze F; Giagounidis A; Götze KS; Krönke J; Sockel K; Middeke JM; Chermat F; Gloaguen S; Puttrich M; Weigt C; William D; Fenaux P; Schlenk RF; Thiede C; Stasik S; Mies A; Adès L; Oelschlägel U; Platzbecker U
    Leukemia; 2020 Apr; 34(4):1182-1186. PubMed ID: 31796915
    [No Abstract]   [Full Text] [Related]  

  • 35. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.
    Silverman LR
    Leuk Res; 2009 Dec; 33 Suppl 2():S18-21. PubMed ID: 20004792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Azacitidine-associated acute interstitial pneumonitis.
    Kuroda J; Shimura Y; Mizutani S; Nagoshi H; Kiyota M; Chinen Y; Maegawa S; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
    Intern Med; 2014; 53(11):1165-9. PubMed ID: 24881742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness and safety of 5-azacitidine in three patients with myelodysplastic syndromes].
    Garzás-Martín de Almagro MC; Gago Sánchez AI; Cuevas Asencio I; Reyes Malia M
    Farm Hosp; 2010; 34(4):204-8. PubMed ID: 20185350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed Onset of Azacitidine-Associated Pneumotitis: A Case Report.
    Oka S; Ono K; Nohgawa M
    Am J Ther; 2019; 26(5):e617-e620. PubMed ID: 30074531
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.